PFE long-term stock decline due to patent losses

Pfizer's long-term stock decline driven by patent losses and reduced growth prospects.

Pfizer's stock has fallen 55% from its late 2021 high, pushing its dividend yield to 6.3%, as investors grapple with the company's patent cliffs on multiple drugs in the coming years. BofA Securities lowered its price target to $26, reflecting updates across large-cap pharma, while Goldman Sachs reset its forecast, maintaining a 'hold' rating. Morgan Stanley highlighted patent concerns, reiterating an 'equal weight' rating. Pfizer's stock has not made a good investment over the past five years, declining by 25% while the S&P 500 climbed by 68%.

Pharmaceutical sector faces valuation repricing and yield concerns.

The pharmaceutical sector is experiencing a repricing, with investors questioning the sustainability of high yields and seeking growth opportunities. Pfizer's dividend, once considered safe, is now under scrutiny. The company's valuation has become incredibly low, trading at a significant discount to its peers. Other large-cap pharma stocks may face similar pressures as patent cliffs and growth concerns come into focus.

Upcoming catalysts: Q1 earnings, patent expirations, and pipeline progress.

Investors should closely watch Pfizer's Q1 earnings, scheduled for May 2, 2023, to gauge the company's current performance and guidance. The upcoming patent expirations for key drugs, such as Vyvanse and Lipitor, will also significantly impact Pfizer's revenue trajectory. Additionally, the progress of Pfizer's pipeline, particularly its COVID-19 vaccine and other innovative therapies, will be crucial in determining the company's long-term growth prospects.